AUROBINDO PHARMA LIMITED
RESULTS FOR Q1 FY 2014-15
(JUNE 2014)
CONSOLIDATED RESULTS TABLE
Aurobindo
Pharma
|
Q1
FY15
|
Q4FY14
|
Dif%
QoQ
|
Q1
FY14
|
Dif%
YoY
|
FY14
|
Net
Sales
|
2895
|
2306
|
25.54
|
1700
|
70.29
|
8038
|
Total
Income
|
2911
|
2330
|
24.94
|
1716
|
69.64
|
8100
|
Total
Exp
|
2344
|
1675
|
39.94
|
1480
|
58.38
|
6280
|
OPT
|
567.32
|
654.93
|
-13.38
|
235.79
|
140.6
|
1820.28
|
PBT
|
560.7
|
666.91
|
-15.93
|
41.91
|
1237.87
|
1532.52
|
NPT
|
415.43
|
501.81
|
-17.21
|
18.6
|
2133.49
|
1172.85
|
EPS-FV.Rs.1
|
14.24
|
17.21
|
-17.26
|
0.64
|
2125
|
40.22
|
Aurobindo
Pharma has produced very good results for Q1 FY 15 ending June 2014. The
consolidated results are in the above table.
Net
Sales have increased 25.54 % on QoQ basis and 70.29 % on YoY basis.
Net
Profit has decreased 17.21% QoQ but has increased 2133% YoY. This is due to
various reasons as mentioned in the Notes to the results.
Taking
into account normal factors and excluding the abnormal factors, the results are
quite gratifying. Future results must show Aurobindo’s performance in a good
light.
Notes
to Accounts Summary :
Sales
for standalone for Q1 FY 15 include exports of Rs.1597.82 cr against Rs.1265.86
cr in corresponding Qtr of last year.
Sales
for Standalone for current Qtr includes dossier income of Rs.66 lakhs against
Rs.2.38 cr in Q1 FY 14.
Forex
gain/loss includes exchange difference of Rs.10.49 cr , Rs.50.48 cr and Rs.50.48
for Q1 FY 15, Q4 FY 14 and Q4 FY 14. It was Rs.202.22 laKhs for FY 2014.
During
the Quarter, Agila Pharma BV Netherlands, a step down subsidiary of the company
has acquired select European Business of Actavis. The consolidated results for
Q1 FY 15 includes this (of Actavis)
On
13.09.13, It was decided to transfer the injectables business to its wholly
owned subsidiary CurePro Parenterals Ltd w.e.f
1-4-2014.It is subject to various approvals and not given effect to in
this results.
The
company has reassessed useful lives of various assets and has charged additional
depreciation of Rs.17.23 cr in standalone and Rs.17.13 Cr in consolidated
results in current Quarter.
Further,
based on transitional provisions in Note 7(b) of Sch.II, an amount of Rs.18.57
cr (Net of deferred tax) has been adjusted in the retained Earnings.
The
Board has approved an interim dividend of Rs.1.50 (150%) per equity share of
Rs.1.
* *
* E N
D * * *